Journal of Biomedical Science | |
Cancer immunotherapies targeting the PD-1 signaling pathway | |
Junzo Hamanishi1  Tasuku Honjo2  Kenji Chamoto2  Yoshiko Iwai3  | |
[1] Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University;Department of Immunology and Genomic Medicine, Graduate School of Medicine, Kyoto University;Department of Molecular Biology, School of Medicine, University of Occupational and Environmental Health Japan; | |
关键词: PD-1; PD-L1; Cancer immunotherapy; Immune checkpoint; | |
DOI : 10.1186/s12929-017-0329-9 | |
来源: DOAJ |
【 摘 要 】
Abstract Immunotherapy has recently emerged as the fourth pillar of cancer treatment, joining surgery, radiation, and chemotherapy. While early immunotherapies focused on accelerating T-cell activity, current immune-checkpoint inhibitors take the brakes off the anti-tumor immune responses. Successful clinical trials with PD-1 monoclonal antibodies and other immune-checkpoint inhibitors have opened new avenues in cancer immunology. However, the failure of a large subset of cancer patients to respond to these new immunotherapies has led to intensified research on combination therapies and predictive biomarkers. Here we summarize the development of PD-1-blockade immunotherapy and current issues in its clinical use.
【 授权许可】
Unknown